Institute for International Research

TIDES 2009 was held May 17-20, 2009 in Las Vegas, NV. The event was a success and a good time was had by all who participated. For 2010, TIDES is making the move to downtown Boston, MA. The event will be held at the Hynes Convention Center, which is in Boston's famed Back Bay area--just a few blocks from Newbury Street, the Prudential Center & Mall and countless bars and restaurants. We look forward to welcoming you to Boston in 2010.

2010 Dates for the TIDES Conference Series:

TIDES 2010: Oligonucleotide and Peptide® Technology and Product Development
April 25-28, 2010 • Hynes Convention Center • Boston, MA, USA
www.IBCLifeSciences.com/TIDES

AsiaTIDES 2010: Oligonucleotide and Peptide® Research, Technology and Product Development
February 22-24, 2010 • Tokyo, Japan
www.IBCLifeSciences.com/AsiaTIDES

Highlight Keynote Presentation Not Just a Message: Noncoding RNAs in Biology and Medicine Thomas R. Cech, Ph.D. Distinguished Professor, University of Colorado-Boulder; Nobel Laureate, 1989 (Chemistry) Sponsored by

Keynote Presentations

	Human Genetics and Oligonucleotides: Essential Partners in Pharma's Future Arthur M. Krieg, M.D. Chief Scientific Officer, Research Technology Center, Pfizer Inc		Peptide Therapeutics: Trends in Global Clinical Development and Approval Janice M. Reichert, Ph.D. Senior Research Fellow, Tufts Center for the Study of Drug Development; Editor-in-Chief, mAbs, Landes Bioscience
	Therapeutic Strategies Using RNA Interference John J. Rossi, Ph.D Lidow Family Research Chair, Professor, Division of Molecular Biology; Dean, Graduate School of Biological Sciences; Beckman Research Institute of City of Hope		Taking Advantage of Peptide Aggregation Joel P. Schneider, Ph.D. Associate Professor, Department of Chemistry and Biochemistry, Department of Materials Science and Engineering, University of Delaware

• Regulatory Strategies: Case Studies from Lilly, Avecia OligoMedicines, OncoGenex, Ipsen, Millennium and Pfizer to Help you Mitigate Economic and Regulatory Risk
• New! Highlights of New Technologies in Two Half-Day Tracks for Oligos and Peptides
  • Novel chemistries define potential licensing opportunities and future manufacturing market needs
  • Delivery technologies for potential market expansion
  • Spray drying for improved product quality and manufacturing throughput with oligo and peptide examples
  • A non-explosive replacement for benzotriazole based coupling reagents
  • Steric blocking oligos and their peptide conjugate technologies for improved targeting of microRNAs
  • Solid and liquid phase synthesis technologies for manufacturing efficiency
• Analytical Technologies for Complex Molecules
  • Hear technical and regulatory strategies from Merck, Bristol-Myers, U. of Washington, Regado, Alnylam and Isis to help you achieve improved characterization and quality control
• Two Full-Day Tracks on Progression from Delivery through Preclinical and Clinical Development with Updates on the Leading Candidates in the Pipeline
  • microRNAs, siRNAs, LNAs, Targeted Delivery, SNALPs, aptamers, Once-Daily GLP-1 Analog, anti-obesity peptides delivered by inhalation, PEG alternative, complement inhibitors, pepducins, Ipsen-Roche collaboration on GLP-1 Analogue, Linaclotide, peptide co-polymer

New Added Benefits to Attending in 2009! Innovation Showcase for late-breaking investment and collaborative opportunities Uncensored strategy discussion forums on the most pressing challenges: Annealing, Adopting New Technologies, Regulatory Challenges, Market Landscapes, and more In-depth courses on Quality Assurance, Manufacturing RNA, Bioanalytical Techniques Customized courses for peptides and oligos on Managing Analytical Development and QC

TIDES® registration also includes access to IBC's 5th International Applications of Nucleic Acids Technologies in Molecular Diagnostics Accelerating Product Development through Cutting Edge Regulatory, Business and Technology Strategies May 19-20, 2009 · Red Rock Casino, Resort & Spa · Las Vegas, NV Keynote Presentations Molecular Diagnostics: Revolution, Regulation and Reimbursement Alberto Gutierrez, Ph.D. Deputy Director, New Product Evaluation, Office of In Vitro Diagnostic Device Evaluation and Safety CDRH, US FDA Reagent Solutions to Challenges in Oligonucleotide Diagnostics Steven A. Benner, Ph.D. Distinguished Fellow Foundation for Applied Molecular Evolution Inc.